N. Sultana

Teaching transposon classification as a means to crowd source the curation of repeat annotation - a tardigrade perspective

The paper presents a crowd-sourcing approach to manually curate and classify transposable elements (TEs) from tardigrade genomes, resulting in the discovery of hundreds of new TEs.

Determining the shelf life of an erythropoietin alfa biosimilar GBPD002 through stability study

This study evaluates the stability of the erythropoietin alfa biosimilar GBPD002 under various environmental conditions and determines its shelf life as 24 months.

Development and qualification of a high-yield recombinant human Erythropoietin biosimilar

This paper develops and characterizes a high-yield biosimilar of recombinant human erythropoietin (rhEPO) that meets regulatory requirements and offers a cost-effective alternative.

A Cost-effective Purification Process for Erythropoietin Biosimilar through Downstream Process Engineering

This study develops a scalable and reproducible downstream purification process for EPO biosimilar, meeting quality requirements and reducing production costs.

Single-agent Foxo1 inhibition normalizes glycemia and induces gut β-like cells in streptozotocin-diabetic mice

This study shows that Foxo1 inhibitors reduce blood glucose and generate gut β-like cells in diabetic mice, suggesting they could be an alternative to insulin.

Triple Notch/Tgfβ/FoxO1 blockade converts multiple intestinal sub-lineages into β-like cells and lowers glycemia in diabetic animals

Genome-wide analysis of long terminal repeat retrotransposons from the cranberry Vaccinium macrocarpon

This study characterizes LTR retrotransposons in the cranberry genome, identifying their abundance, structure, and activity, and highlights potential markers for breeding.

BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response

This paper develops and characterizes an mRNA-LNP vaccine candidate targeting the D614G variant of SARS-CoV-2, showing neutralizing antibody and balanced cellular immune responses in preclinical trials.